1845PSafety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials. (23rd October 2018) - Mau-Sorensen, M; van Bussel, M; Kuipers, M; Nielsen, D L; Verheul, H M; Aftimos, P; de Jonge, M J A; van Triest, B; Falkenius, J; Debus, J; Troost, E; Samuels, M; et al.